Page 2 - Transcode Therapeutics News Today

Verve Therapeutics (NASDAQ:VERV – Get Free Report) and TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Valuation and Earnings This table compares Verve […]

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

TransCode Therapeutics, Inc.?s co-founder and Chief Executive Officer, Michael Dudley, announced his retirement. He will resign as an executive officer of the company effective January 13, 2024....

-- TransCode Therapeutics said late Friday it has taken additional steps in a previously announced restructuring to cut expenses and allow a greater concentration of resources on a planned phase 1...

An Open Letter to Shareholders of TransCode Therapeutics, Inc....

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 437,500 shares, a decline of 31.3% from the November 30th total of 637,200 shares. Currently, 2.0% of the shares of the stock are […]

HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock. TransCode Therapeutics Stock Performance TransCode Therapeutics stock opened at $1.78 on Wednesday. TransCode Therapeutics has a 52-week low of $0.42 […]

HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a $3.00 target price on the stock. TransCode Therapeutics Stock Performance NASDAQ:RNAZ opened at $1.78 on Wednesday. The firm has a market cap of $11.75 million, a […]